HGEN News and Press, Humanigen Inc. From 06/30/20

ZUMA-19 study being conducted as part of a clinical collaboration in the U.S. Study evaluating the potential effects of lenzilumab (anti-human-GM-CSF monoclonal antibody) prior to Yescarta® (axicabtagene ciloleucel) in adults with relapsed or refractory large B-cell lymphoma...

Lenzilumab median time to recovery of five days compares favorably to remdesivir’s 10 days in a similar patient group Lenzilumab Phase 3 potential registration study ongoing in severe and critical COVID-19 patients Humanigen to host a webinar today at 4:30 p.m. ET to di...

Humanigen ( OTCQB:HGEN +37.3% ) announces data on the first clinical use of lenzilumab, the proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor, in 12 COVID-19 patients. More news on: Humanigen, Inc., Healthcare stocks news, Read m...

Median time to recovery and discharge of five days All patients were at high risk of progression, including four patients who were in the ICU prior to receiving lenzilumab No treatment emergent adverse events were attributable to lenzilumab BURLINGAME, CA / ACCESSWIRE / June 15, ...

The need for medicines that help Covid-19 patients before the disease leaves the viral response phase and enters the host inflammatory phase has never been greater. While there are some positive signals in the prevention area, the most frequent estimates I am reading place a realistic timeli...

J.P. Morgan Securities LLC acting as placement agent Financing syndicate includes Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), HealthCor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital BURLINGAME, CA / ACCESSWIRE / June ...

BURLINGAME, CA / ACCESSWIRE / June 1, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company's proprietary Humaneered ® anti-human granulocyte macrophage-colony s...

First Phase III Pivotal Study for an anti-GM-CSF Therapy in COVID-19 Patients First US randomized, double-blind, placebo-controlled, multi-center, Phase III study with an anti-GM-CSF monoclonal antibody which, if successful, may lead to lenzilumab product approval for COVID-19 Ta...

The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...

Company to Begin Enrolling Patients as Soon as Possible at Several Leading Centers Phase III study enrollment to focus on adult, hospitalized patients with COVID-19 pneumonia and at high risk of progression to respiratory failure US multi-center, randomized, placebo-controlled, do...